

Clinical trials of sirolimus eluting stent

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
sirolimus eluting stent vs bare-metal stent			
DEBATER (SES vs BMS) , 2009 n=424/446 follow-up: 1 y	sirolimus-eluting stents versus bare-metal stents	patients undergoing PCI for STEMI withon 12 hours	Factorial plan
Daz de la Llera , 2007 n=60/54 follow-up: 1y	sirolimus-eluting stents versus uncoated stents	primary percutaneous coronary intervention for acute myocardial infarction with ST-segment elevation	Parallel groups open Spain
MISSION , 2008 [ISRCTN62825862] n=158/152 follow-up: 12 months	Cypher versus Vision	primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h)	Parallel groups single-blind the Netherlands
SESAMI , 2007 [NCT00288210] n=160/160 follow-up: 12 months	Cypher versus BX stent, Cordis	AMI	Parallel groups open Italy
TYPHOON , 2006 [NCT00232830] n=356/359 follow-up: 12 months	Cypher or CypherSelect versus any commerciallyavailable uncoated stent	AMI	Parallel groups open Worldwide (15 countries)
sirolimus eluting stent vs paclitaxel eluting stent			
Di Lorenzo et al. , 2005 <i>unpublished</i> n=90/90 follow-up:	sirolimus versus paclitaxel	ST-segment elevation myocardial infarction	Parallel groups open
Juwana , 2009 [ISRCTN90526229] n=196/201 follow-up: 9 months (12 months)	sirolimus coated Cypher stent versus paclitaxel coated Taxus stent	patients with STEMI undergoing primary PCI	Parallel groups open The Netherlands

continued...

Trial	Treatments	Patients	Trials design and methods
PROSIT , 2006 n=154/154 follow-up: 1 year	SES Cordis versus PES Boston Scientific	AMI or persistent ischaemia 12-24h	Parallel groups open Korea

More details and results :

- myocardial revascularization for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q129>
- PCI for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q246>

References

DEBATER (SES vs BMS), 2009:

Daz de la Llera, 2007:

Daz de la Llera LS, Ballesteros S, Nevado J, Fernndez M, Villa M, Snchez A, Retegui G, Garca D, Martnez A Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. *Am Heart J* 2007;154:164.e1-6 [[17584571](#)]

MISSION, 2008:

van der Hoeven BL, Liem S, Jukema JW, et al. Prospectiverandomised trial to evaluate the effi cacy and safety of drug-elutingstents versus bare-metal stents for the treatment of acutemyocardial infarction (the MISSION! intervention study) AnnualScientifi c Meeting of the American Heart Association. Chicago, IL,USA; Nov 1215, 2006.

van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schali j MJ Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. *J Am Coll Cardiol* 2008 Feb 12;51:618-26 [[18261680](#)]

SESAMI, 2007:

Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). *J Am Coll Cardiol* 2007;49:1924-30 [[17498576](#)]

Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli R Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Results of the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction) Trial. *J Am Coll Cardiol* 2010 Feb 23;55:810-814 [[20170821](#)] [10.1016/j.jacc.2009.09.046](https://doi.org/10.1016/j.jacc.2009.09.046)

TYPHOON, 2006:

Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C Sirolimus-eluting versus uncoated stents in acute myocardial infarction. *N Engl J Med* 2006;355:1093-104 [[16971716](#)]

Di Lorenzo et al., 2005:

unpublished

Di Lorenzo E, Varricchio A, Lanzillo T, et al. Paclitaxel and sirolimusstent implantation in patients with acute myocardial infarction (abstr) *Circulation* 2005;112:U538

Juwana, 2009:

Juwana YB, Suryapranata H, Ottervanger JP, De Luca G, van't Hof AW, Dambrink JH, de Boer MJ, Gosselink AT, Hoorntje JC Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. *Am J Cardiol* 2009;104:205-9 [19576348]

PROSIT, 2006:

Lee JH, Kim HS, Lee SW, et al. Prospective randomized trial of asirolimus eluting versus a paclitaxel eluting stent for the treatment of acute ST-elevation myocardial infarction Annual Scientific Meeting of the American College of Cardiology; Atlanta, GA, USA; March 11-14, 2006.

Kornowski R Drug-eluting stents in ST elevation myocardial infarction: In light of the PROSIT trial. *Catheter Cardiovasc Interv* 2008 Jul 1;72:33-5 [18561153]

Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, Cho Y, Lee N, Rhee KS, Ko JK, Seong IW Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. *Catheter Cardiovasc Interv* 2008 Jul 1;72:25-32 [18412270]

2 stable angina

Trial	Treatments	Patients	Trials design and methods
sirolimus eluting stent vs bare-metal stent			
C-SIRIUS , 2004 [NCT00381420] n=50/50 follow-up: 9 months	coated Bx-VELOCITY versus Bx-VELOCITY	Stable or unstable AP, silent ischaemia	Parallel groups double-blind Canada
DECODE , 2005 <i>unpublished</i> [NCT00489164] n=54/29 follow-up: 1 year	CYPHER (Up to 3 stents per patient were allowed) versus Bx VELOCITY (Up to 3 stents per patient were allowed)	Stable or unstable angina in diabetic patients with up to 2 de novo lesions in up to 2 native coronary vessels	Parallel groups open US, Asia/Pacific
DESSERT , 2008 n=75/75 follow-up: 12 months	Cypher and Cypher Select versus Sonic (Cordis)	de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >3 months	Parallel groups single-blind Italy
DIABETES , 2005 n=80/80 follow-up: 9 months	Cypher versus Bx Velocity/Sonic	de novo lesions in native coronary arteries in 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm	Parallel groups open Spanish
E-SIRIUS , 2003 [NCT00235144] n=175/177 follow-up: 9 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment	Parallel groups open Europe

continued...

Trial	Treatments	Patients	Trials design and methods
GISSOC II , 2010 [NCT00220558] n=78/74 follow-up: 8 months	Sirolimus Eluting Stent versus Bare Metal Stent	patients with Chronic Total Occlusion older than 1 month, and successful recanalization	Parallel groups open Italy
Kochiadakis , 2007 n=38/43 follow-up: 4.8 months (mean)	sirolimus-eluting stents versus bare metal stent	one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm	Parallel groups open Greece
Ortolani et al , 2007 n=NA follow-up: 9 months	Cypher versus Vision	symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent	Parallel groups single-blind
Pache et al , 2005 n=250/250 follow-up: 12 months	Cypher versus BeStent 2	with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels	Parallel groups open Germany
Pasceri , 2003 <i>unpublished</i> n=NA follow-up: 12 months	-	-	Parallel groups
PRISON II , 2006 [NCT00258596] n=100/100 follow-up: 6 months	Cypher versus BxVelocity	Chronic total occlusion, positive exercise stress test	Parallel groups single-blind Belgium
RAVEL , 2002 [NCT00233805] n=120/118 follow-up: 12 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery	Parallel groups double-blind Global
SCANDSTENT , 2006 [NCT00151658] n=163/159 follow-up: 7 months	Cypher versus Sonic	Stable or unstable AP, recent AMI (non ST-elevation); with one or more de novo complex lesions in native coronary vessels (occluded, bifurcational, ostial or angulated)	Parallel groups open Denmark
SCORPIUS , 2007 [NCT00495898] n=98/102 follow-up: 12 months	Cypher versus Bx-Velocity	patients with diabetes and de novo coronary artery lesions	Parallel groups open Germany
SES-SMART , 2004 n=129/128 follow-up: 8 months	Cypher versus Bx Sonic	Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test	Parallel groups single-blind Italian

continued...

Trial	Treatments	Patients	Trials design and methods
SIRIUS , 2003 [NCT00232765] n=533/525 follow-up: 9 months	SES versus Bx Velocity	Stable or unstable AP, signs of myocardial ischaemia	Parallel groups double-blind United States
sirolimus eluting stent vs cutting ballon angioplasty			
FOCUS <i>ongoing</i> [NCT00485004] n=NA follow-up:	sirolimus-eluting implantation cypher versus cutting balloon angioplasty	focal in-stent restenosis after drug-eluting stent	
sirolimus eluting stent vs paclitaxel eluting stent			
BASKET (vs paclitaxel) , 2005 n=264/281 follow-up: 6 months	Cypher versus Taxus	Unselected patients; de-novo lesions	Parallel groups open Switzerland,
Cervinka , 2006 n=37/33 follow-up: 6 months	sirolimus-eluting stent versus paclitaxel-eluting stent	Complex lesionsand patients. Signs and/or symptoms myocardial ischaemia, including AMI	Parallel groups open
CORPAL , 2005 <i>unpublished</i> n=331/321 follow-up:	sirolimus versus paclitaxel	Documented myocardial ischaemia, no AMI	Parallel groups open Spain
Di Lorenzo et al. , 2005 <i>unpublished</i> n=90/90 follow-up:	sirolimus versus paclitaxel	ST-segment elevation myocardial infarction	Parallel groups open
Han , 2006 n=210/206 follow-up: 19.5 months (mean)	Cypher versus Taxus	Multivessel disease. Stable or unstable AP, no AMI	Parallel groups open China
ISAR-DESIRE (SES vs PES) , 2005 n=100/100 follow-up: 1y	Cypher versus Taxus	In-stent restenosis. AP and/or positive test, previously stented, no AMI	Parallel groups open germany
ISAR-DIABETES , 2005 n=125/125 follow-up: 9 months	Taxus versus Cypher	Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel	Parallel groups open Germany

continued...

Trial	Treatments	Patients	Trials design and methods
ISAR-LEFT-MAIN , 2009 [NCT00133237] n=302/305 follow-up: 1 year	Paclitaxel-eluting stent versus Sirolimus-eluting stent	Unprotected Left Main Coronary Artery Disease	Parallel groups open
ISAR-SMART 3 , 2006 [NCT00146575] n=180/180 follow-up:	Taxus versus Cypher	Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMI	Parallel groups NA Germany
ISAR-TEST-1 , 2006 [NCT00140530] n=225/225 follow-up: 9 months	rapamycin-eluting stent Yukon versus Taxus	stable or unstable angina or a positive stress test, stable or unstable angina or a positive stress test	Parallel groups open Germany
Kim , 2008 n=85/84 follow-up: 6 months	Cypher versus Taxus	Korean diabetic patients with high-grade de novo coronary lesions (stenosis of >70 percent of the luminal diameter) requiring <3 stents	Parallel groups open Korea
LONG DES II , 2006 n=250/250 follow-up: 9 months	SES versus PES	Long lesions. AP or positive stress, no AMI	Parallel groups single-blind Korea
Petronio et al , 2007 n=50/50 follow-up: 9 months	Cypher versus Taxus	Complex lesions. Stable AP or documented ischaemia, no AMI	Parallel groups open Italy
REALITY , 2006 [NCT00235092] n=701/685 follow-up: 12 months	Cypher versus Taxus	Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries	Parallel groups open Europe, Latin America, and Asiam
SIRTAX (Windecker) , 2005 n=503/509 follow-up: 9 mo (5y)	sirolimus-eluting stents (Cypher) versus paclitaxel-eluting stents (Taxus)	Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation	Parallel groups single-blind Switzerland
TAXi , 2005 n=102/100 follow-up: 6 months	Cypher versus Taxus	Unselected patients	Parallel groups open Switzerland.

continued...

Trial	Treatments	Patients	Trials design and methods
Tomai , 2008 n=60/60 follow-up: 8 months	sirolimus-eluting stent versus paclitaxel-eluting stent	diabetic patient with multiple de novo coronary artery lesions	Cross over NA Italy
Zhang (SES vs PES) , 2006 n=246/203 follow-up: 1y	Cypher versus Taxus	Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions	Parallel groups open China
DES-ISR <i>ongoing</i> [NCT00485030] n=NA follow-up:	Cypher versus Taxus	patients Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation	
Lipsia-Yukon-DM <i>ongoing</i> [NCT00368953] n=NA follow-up: 9 months	Yukon Choice stent system versus Taxus Libert stent system	Patients With Diabetes Mellitus	
sirolimus eluting stent vs CABG			
MIDCAB Versus DES in Proximal LAD Lesions <i>ongoing</i> [NCT00299429] n=NA follow-up:	sirolimus-coated stent versus minimally invasive bypass surgery	patients with isolated proximal left anterior descending coronary arteries	

More details and results :

- myocardial revascularization for stable angina in all type of patient at <http://www.trialresultscenter.org/go-Q25>
- myocardial revascularization for stable angina in diabetic patients at <http://www.trialresultscenter.org/go-Q29>

References

C-SIRIUS, 2004:

Schampaert E, Cohen EA, Schlter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5 [15028375]

DECODE, 2005:

unpublished

Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M. Outcomes in diabetic patients with multivessel disease and long lesions: results from the DECODE study Am J Cardiol 2005; 96 (suppl 7A): 31H

DESSERT, 2008:

Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P, Zoccai GB Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). *Am J Cardiol* 2008;101:1560-6 [[18489933](#)]

DIABETES, 2005:

Sabat M, Jimnez-Quevedo P, Angiolillo DJ, Gmez-Hospital JA, Alfonso F, Hernndez-Antoln R, Goicolea J, Baelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. *Circulation* 2005;112:2175-83 [[16203930](#)]

Jimnez-Quevedo P, Sabat M, Angiolillo DJ, Alfonso F, Hernndez-Antoln R, SanMartn M, Gmez-Hospital JA, Baelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. *Eur Heart J* 2007;28:1946-52 [[17562666](#)]

Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L *Am J Cardiol* 2009 Feb 1;103:345-9 [[19166687](#)]

E-SIRIUS, 2003:

Schofer J, Schlter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet* 2003;362:1093-9 [[14550694](#)]

GISSOC II, 2010:

Rubartelli P, Petronio AS, Guiducci V, Sganzerla P, Bolognese L, Galli M, Sheiban I, Chirillo F, Ramondo A, Bellotti S Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. *Eur Heart J* 2010;: [[20566487](#)]
[10.1093/eurheartj/ehq199](https://doi.org/10.1093/eurheartj/ehq199)

Kochiadakis, 2007:

Kochiadakis GE, Marketou ME, Arfanakis DA, Sfridaki K, Skolidis EI, Igoumenidis NE, Hamilos MI, Kolyvaki S, Chlouverakis G, Kantidaki E, Castanas E, Vardas PE, Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. *Atherosclerosis* 2007;194:433-8. [[16997310](#)] [10.1016/j.atherosclerosis.2006.08.029](https://doi.org/10.1016/j.atherosclerosis.2006.08.029)

Ortolani et al, 2007:

Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F, Silenzi S, Cooke RM, Reggiani ML, Branzi A Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. *Catheter Cardiovasc Interv* 2007;69:790-8 [[17290437](#)]

Pache et al, 2005:

Pache J, Dibra A, Mehilli J, Dirschinger J, Schmig A, Kastrati A Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. *Eur Heart J* 2005;26:1262-8 [[15737962](#)]

Pasceri, 2003:

unpublished

Pasceri V, Granatelli A, Pristipino C, et al. A randomized trial of arapamycin-eluting stent in acute myocardial infarction: preliminary results TCT 2003. *Am J Cardiol* 2003;92(Suppl 6A):1L.

PRISON II, 2006:

Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. *Circulation* 2006;114:921-8 [[16908768](#)]

RAVEL, 2002:

Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnr F, Falotico R A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002;346:1773-80 [[12050336](#)]

Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. *J Am Coll Cardiol* 2007 Oct 2;50:1299-304 [[17903626](#)]

SCANDSTENT, 2006:

Kelbaek H, Thuesen L, Helqvist S, Klvgaard L, Jrgensen E, Aljabbari S, Saunamki K, Krusell LR, Jensen GV, Btker HE, Lassen JF, Andersen HR, Thayssen P, Galle A, van Weert A The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. *J Am Coll Cardiol* 2006;47:449-55 [[16412876](#)]

Kelbaek H, Klvgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrm T, Btker HE, Jrgensen E, Saunamki K, Aljabbari S, Thayssen P, Galle A, Jensen GV, Thuesen L Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. *J Am Coll Cardiol* 2008 May 27;51:2011-6 [[18498953](#)]

SCORPIUS, 2007:

Baumgart D. One year results of the SCORPIUS-Trial - a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients Annual Scientific Meeting of the Transcatheter Cardiovascular Therapeutics. Washington, DC; Oct 22-27, 2006. Abstract 288.

Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Vlker W, Pfannebecker T, Stoll HP, Nickenig G One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. *J Am Coll Cardiol* 2007 Oct 23;50:1627-34 [[17950142](#)]

SES-SMART, 2004:

Ardisino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. *JAMA* 2004;292:2727-34 [[15585732](#)]

SIRIUS, 2003:

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003;349:1315-23 [[14523139](#)]

Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MB Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). *Am J Cardiol* 2007 Apr 15;99:1044-50 [[17437725](#)]

Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. *Circulation* 2004;109:634-40 [[14769686](#)]

Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. *J Am Coll Cardiol* 2009 Apr 28;53:1488-97 [[19389558](#)]
[10.1016/j.jacc.2009.01.050](#)

Novack V, Nguyen MC, Rooney M, Chacko R, Novack L, Pencina M, Apruzzese P, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DE Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. *Am J Cardiol* 2010 Sep 15;106:774-9 [[20816116](#)] [10.1016/j.amjcard.2010.04.039](#)

FOCUS, 0:

ongoing trial NCT00485004

BASKET (vs paclitaxel), 2005:

Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). *Lancet* 2005;366:921-9 [16154019]

Cervinka, 2006:

Cervinka P, Costa MA, Angiolillo DJ, Spacek R, Bystron M, Kvasnik M, Veselka J, Nanda H, Futamatsu H, Futamatsu K "Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study". *Catheter Cardiovasc Interv* 2006;67:846-51 [16683273]

CORPAL, 2005:

unpublished

de Lezo J, Medina A, Pan M, et al. de Lezo J, Medina A, Pan M, et al. Drug-eluting stent for complex lesions: latest angiographic data from randomized rapamycin versus paclitaxel CORPAL study *J Am Coll Cardiol* 2005; 45: 75A.

Di Lorenzo et al., 2005:

unpublished

Di Lorenzo E, Varricchio A, Lanzillo T, et al. Paclitaxel and sirolimus stent implantation in patients with acute myocardial infarction (abstr) *Circulation* 2005;112:U538

Han, 2006:

Han YL, Wang XZ, Jing QM, Wang SL, Ma YY, Luan B [Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease] *Zhonghua Xin Xue Guan Bing Za Zhi* 2006;34:123-6 [16626577]

ISAR-DESIRE (SES vs PES), 2005:

Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig A Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 2005;293:165-71 [15644543]

ISAR-DIABETES, 2005:

Dibra A, Kastrati A, Mehilli J, Pache J, Schhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schmig A Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *N Engl J Med* 2005;353:663-70 [16105990]

ISAR-LEFT-MAIN, 2009:

Mehilli J, Kastrati A, Byrne RA, Bruskin O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schmig A Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2009 May 12;53:1760-8 [19422982]

ISAR-SMART 3, 2006:

Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schmig A Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. *Eur Heart J* 2006;27:260-6 [16401670]

ISAR-TEST-1, 2006:

Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schmig A Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. *Circulation* 2006;113:273-9 [16391155]

Kim, 2008:

Kim MH, Hong SJ, Cha KS, Park HS, Chae SC, Hur SH, Gwon HC, Bae JH, Lim DS Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. *J Interv Cardiol* 2008 Jun;21:225-31 [18341520]

LONG DES II, 2006:

Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. *Circulation* 2006;114:2148-53 [[17060388](#)]

Petronio et al, 2007:

Petronio AS, De Carlo M, Branchitta G, Papini B, Ciabatti N, Gistri R, Cortese B, Gherarducci G, Barsotti A Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. *J Am Coll Cardiol* 2007;49:539-46 [[17276176](#)]

REALITY, 2006:

Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. *JAMA* 2006;295:895-904 [[16493102](#)]

SIRTAX (Windecker), 2005:

Windecker S, Remondino A, Eberli FR, Jni P, Rber L, Wenaweser P, Togni M, Billinger M, Tller D, Seiler C, Roffi M, Corti R, Stsch G, Maier W, Lscher T, Hess OM, Egger M, Meier B Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. *N Engl J Med* 2005;353:653-62 [[16105989](#)]

TAXi, 2005:

Goy JJ, Stauffer JC, Siegenthaler M, Benot A, Seydoux C A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. *J Am Coll Cardiol* 2005;45:308-11 [[15653032](#)]

Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benot A, Goy JJ Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. *Catheter Cardiovasc Interv* 2007 Aug 1;70:163-6 [[17630653](#)]

Tomai, 2008:

Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffr G, Prati F, Tamburino C, Ribichini F, Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. *Diabetes Care* 2008;31:15-9. [[17909090](#)] [10.2337/dc07-1377](#)

Zhang (SES vs PES), 2006:

Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ni J, Fang YH, Zhang X, Shen WF One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. *Chin Med J (Engl)* 2006;119:165-8 [[16455001](#)]

DES-ISR, 0:

ongoing trial NCT00485030

Lipsia-Yukon-DM, 0:

ongoing trial NCT00368953

MIDCAB Versus DES in Proximal LAD Lesions, 0:

ongoing trial NCT00299429

3 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
sirolimus eluting stent vs balloon angioplasty			

continued...

Trial	Treatments	Patients	Trials design and methods
ISAR-DESIRE (SES vs PTCA) , 2005 n=100/100 follow-up: 1y	Cypher versus ballon angioplasty	In-stent restenosis. AP and/or positive test, previously stented, no AMI	Parallel groups open germany
sirolimus eluting stent vs bare-metal stent			
BASKET-PROVE (SES) , 2010 [ISRCTN72444640] n=775/765 follow-up: 2 years	first-generation sirolimus-eluting stent versus BMS	patients needing stents 3.0 mm or larger	Parallel groups open Switzerland, Denmark, Austria, Italy
C-SIRIUS , 2004 [NCT00381420] n=50/50 follow-up: 9 months	coated Bx-VELOCITY versus Bx-VELOCITY	Stable or unstable AP, silent ischaemia	Parallel groups double-blind Canada
DEBATER (SES vs BMS) , 2009 n=424/446 follow-up: 1 y	sirolimus-eluting stents versus bare-metal stents	patients undergoing PCI for STEMI withon 12 hours	Factorial plan
DECODE , 2005 <i>unpublished</i> [NCT00489164] n=54/29 follow-up: 1 year	CYPHER (Up to 3 stents per patient were allowed) versus Bx VELOCITY (Up to 3 stents per patient were allowed)	Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels	Parallel groups open US, Asia/Pacific
DESSERT , 2008 n=75/75 follow-up: 12 months	Cypher andCypher Select versus Sonic (Cordis)	de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >3 months	Parallel groups single-blind Italy
DIABETES , 2005 n=80/80 follow-up: 9 months	Cypher versus Bx Velocity/Sonic	de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm	Parallel groups open Spanish
Daz de la Llera , 2007 n=60/54 follow-up: 1y	sirolimus-eluting stents versus uncoated stents	primary percutaneous coronary intervention for acute myocardial infarction with ST-segment elevation	Parallel groups open Spain

continued...

Trial	Treatments	Patients	Trials design and methods
E-SIRIUS , 2003 [NCT00235144] n=175/177 follow-up: 9 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment	Parallel groups open Europe
GISSOC II , 2010 [NCT00220558] n=78/74 follow-up: 8 months	Sirolimus Eluting Stent versus Bare Metal Stent	patients with Chronic Total Occlusion older than 1 month, and successful recanalization	Parallel groups open Italy
Kochiadakis , 2007 n=38/43 follow-up: 4.8 months (mean)	sirolimus-eluting stents versus bare metal stent	one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm	Parallel groups open Greece
MISSION , 2008 [ISRCTN62825862] n=158/152 follow-up: 12 months	Cypher versus Vision	primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h)	Parallel groups single-blind the Netherlands
Ortolani et al , 2007 n=NA follow-up: 9 months	Cypher versus Vision	symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent	Parallel groups single-blind
Pache et al , 2005 n=250/250 follow-up: 12 months	Cypher versus BeStent 2	with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels	Parallel groups open Germany
Pasceri , 2003 <i>unpublished</i> n=NA follow-up: 12 months	-	-	Parallel groups
PRISON II , 2006 [NCT00258596] n=100/100 follow-up: 6 months	Cypher versus BxVelocity	Chronic total occlusion, positive exercise stress test	Parallel groups single-blind Belgium
RAVEL , 2002 [NCT00233805] n=120/118 follow-up: 12 months	coated Bx Velocity versus Bx Velocity	Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery	Parallel groups double-blind Global

continued...

Trial	Treatments	Patients	Trials design and methods
Ravel (diabetics) , 2004 n=19/25 follow-up: 6 months	coated Bx velocity versus Bx VELOCITY	sub groups of diabetic patients with de novo native coronary artery lesions 2.5 to 3.5 mm in diameter by visual assessment that could be covered by an 18-mm stent	Parallel groups NA Europe
RRISC , 2006 [NCT00263263] n=38/37 follow-up: 6 months (3 years)	Cypher versus BX-Velocity	Stable or unstable AP, with previous coronary artery bypass surgery and degenerated vein grafts	Parallel groups open Belgium, The netherlands
SCANDSTENT , 2006 [NCT00151658] n=163/159 follow-up: 7 months	Cypher versus Sonic	Stable or unstable AP, recent AMI (non ST-elevation); with one or more de novo complex lesions in native coronary vessels (occluded, bifurcational, ostial or angulated)	Parallel groups open Denmark
SCANDSTENT (subgroup) , 2006 n=64/63 follow-up: 17 mo (angiography 7 mo)	SES implanted after successful recanalization versus BMS implanted after successful recanalization	patients with coronary artery disease and a total coronary occlusion ≥ 15 mm in length	Parallel groups open
SCORPIUS , 2007 [NCT00495898] n=98/102 follow-up: 12 months	Cypher versus Bx-Velocity	patients with diabetes and de novo coronary artery lesions	Parallel groups open Germany
SES-SMART , 2004 n=129/128 follow-up: 8 months	Cypher versus Bx Sonic	Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test	Parallel groups single-blind Italian
SES-SMART (diabetics) , 2005 n=29/45 follow-up: 8 months	Cypher versus Bx Sonic	Diabetic patients with de novo target lesion ≤ 2.75 mm in diameter in a native coronary artery that could be completely covered by a single stent (maximum length 33 mm)	Parallel groups single-blind Italy
SESAMI , 2007 [NCT00288210] n=160/160 follow-up: 12 months	Cypher versus BX stent, Cordis	AMI	Parallel groups open Italy

continued...

Trial	Treatments	Patients	Trials design and methods
SIRIUS , 2003 [NCT00232765] n=533/525 follow-up: 9 months	SES versus Bx Velocity	Stable or unstable AP, signs of myocardial ischaemia	Parallel groups double-blind United States
SIRIUS (diabetics) , 2003 n=131/148 follow-up: 12 months	SES versus BMS	sub group of diabetics patients of SIRIUS study	Parallel groups double-blind US
TYPHOON , 2006 [NCT00232830] n=356/359 follow-up: 12 months	Cypher or CypherSelect versus any commerciallyavailable uncoated stent	AMI	Parallel groups open Worldwide (15 countries)
BASKET-PROVE , 2008 <i>ongoing</i> n=NA follow-up:	Cypher versus Vision	-	
sirolimus eluting stent vs PTCA			
CRISTAL [NCT00323895] n=NA follow-up:	sirolimus-eluting stent versus balloon re-percutaneous transluminal coronary angioplasty	Intra-Des Restenosis	
RIBS-II , 2008 n=76/74 follow-up: >1 year	sirolimus-eluting stents versus Balloon angioplasty	patients with bare metal in-stent restenosis	Parallel groups open Spanish
sirolimus eluting stent vs cutting ballon angioplasty			
FOCUS <i>ongoing</i> [NCT00485004] n=NA follow-up:	sirolimus-eluting implantation cypher versus cutting balloon angioplasty	focal in-stent restenosis after drug-eluting stent	
sirolimus eluting stent vs brachytherapy			
SISR , 2007 [NCT00231257] n=259/125 follow-up: 12 months	Sirolimus-eluting stents versus brachytherapy	restenosis within a bare metal stent	Parallel groups open US and Canadian
sirolimus eluting stent vs paclitaxel eluting stent			

continued...

Trial	Treatments	Patients	Trials design and methods
BASKET (vs paclitaxel) , 2005 n=264/281 follow-up: 6 months	Cypher versus Taxus	Unselected patients; de-novo lesions	Parallel groups open Switzerland,
Cervinka , 2006 n=37/33 follow-up: 6 months	sirolimus-eluting stent versus paclitaxel-eluting stent	Complex lesions and patients. Signs and/or symptoms myocardial ischaemia, including AMI	Parallel groups open
CORPAL , 2005 <i>unpublished</i> n=331/321 follow-up:	sirolimus versus paclitaxel	Documented myocardial ischaemia, no AMI	Parallel groups open Spain
DES-DIABETES , 2008 n=200/200 follow-up: 9 months (1 year)	sirolimus-eluting stent versus paclitaxel-elutingstent	diabetic patients with angina pectoris and/or a positive stress test and a native coronary lesion	Factorial plan open Korea
Di Lorenzo et al. , 2005 <i>unpublished</i> n=90/90 follow-up:	sirolimus versus paclitaxel	ST-segment elevation myocardial infarction	Parallel groups open
Han , 2006 n=210/206 follow-up: 19.5 months (mean)	Cypher versus Taxus	Multivessel disease. Stable or unstable AP, no AMI	Parallel groups open China
ISAR-DESIRE (SES vs PES) , 2005 n=100/100 follow-up: 1y	Cypher versus Taxus	In-stent restenosis. AP and/or positive test, previously stented, no AMI	Parallel groups open germany
ISAR-DESIRE-2 , 2010 [NCT00598715] n=225/225 follow-up: 1y	sirolimus-eluting stent versus paclitaxel-eluting stent	coronary restenosis in sirolimus-eluting stents	Parallel groups open Germany
ISAR-DIABETES , 2005 n=125/125 follow-up: 9 months	Taxus versus Cypher	Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel	Parallel groups open Germany
ISAR-LEFT-MAIN , 2009 [NCT00133237] n=302/305 follow-up: 1 year	Paclitaxel-eluting stent versus Sirolimus-eluting stent	Unprotected Left Main Coronary Artery Disease	Parallel groups open

continued...

Trial	Treatments	Patients	Trials design and methods
ISAR-SMART 3 , 2006 [NCT00146575] n=180/180 follow-up:	Taxus versus Cypher	Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMI	Parallel groups NA Germany
ISAR-TEST-1 , 2006 [NCT00140530] n=225/225 follow-up: 9 months	rapamycin-eluting stent Yukon versus Taxus	stable or unstable angina or a positive stress test, stable or unstable angina or a positive stress test	Parallel groups open Germany
Kim , 2008 n=85/84 follow-up: 6 months	Cypher versus Taxus	Korean diabetic patients with high-grade de novo coronary lesions (stenosis of >70 percent of the luminal diameter) requiring <3 stents	Parallel groups open Korea
LONG DES II , 2006 n=250/250 follow-up: 9 months	SES versus PES	Long lesions. AP or positive stress, no AMI	Parallel groups single-blind Korea
Pan , 2007 n=103/102 follow-up: 24 months (mean)	SES for provisional T-stenting versus PES for provisional T-stenting	patients with bifurcation lesions	Parallel groups open Spain
Petronio et al , 2007 n=50/50 follow-up: 9 months	Cypher versus Taxus	Complex lesions. Stable AP or documented ischaemia, no AMI	Parallel groups open Italy
PROSIT , 2006 n=154/154 follow-up: 1 year	SES Cordis versus PES Boston Scientific	AMI or persistent ischaemia 12-24h	Parallel groups open Korea
REALITY , 2006 [NCT00235092] n=701/685 follow-up: 12 months	Cypher versus Taxus	Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries	Parallel groups open Europe, Latin America, and Asiam
REALITY (diabetics) , 2006 unpublished n=187/192 follow-up: 12 months	SES versus PES	-	Parallel groups open worldwide

continued...

Trial	Treatments	Patients	Trials design and methods
SIRTAX (small vessels subgroup) , 2005 n=249/246 follow-up: 9 months	Cypher versus Taxus	Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation	Parallel groups single-blind Switzerland
SIRTAX (Windecker) , 2005 n=503/509 follow-up: 9 mo (5y)	sirolimus-eluting stents (Cypher) versus paclitaxel-eluting stents (Taxus)	Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation	Parallel groups single-blind Switzerland
SIRTAX diabetics , 2005 [NCT00297661] n=108/93 follow-up: 12 months	Cypher versus Taxus	Sub groups of diabetics patients with either stable angina or an acute coronary syndrome	Parallel groups single-blind Switzerland
SORT OUT II , 2008 [NCT00388934] n=1065/1033 follow-up:	Cypher stent versus Taxus stent(Boston Scientific Corp)	Unselected patients (included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina)	Parallel groups open Denmark.
TAXi , 2005 n=102/100 follow-up: 6 months	Cypher versus Taxus	Unselected patients	Parallel groups open Switzerland.
TAXi (diabetics) , 3000 <i>unpublished</i> n=33/36 follow-up: 12 months	SES versus PES	-	Parallel groups open Switzerland
Tomai , 2008 n=60/60 follow-up: 8 months	sirolimus-eluting stent versus paclitaxel-eluting stent	diabetic patient with multiple de novo coronary artery lesions	Cross over NA Italy
Wessely , 2008 n=NA follow-up: 9 months	rapamycin polymer-coated drug-eluting stent versus paclitaxel polymer-coated drug-eluting stent	-	Parallel groups NA Germany

continued...

Trial	Treatments	Patients	Trials design and methods
Zhang (SES vs PES) , 2006 n=246/203 follow-up: 1y	Cypher versus Taxus	Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions	Parallel groups open China
DES-ISR ongoing [NCT00485030] n=NA follow-up:	Cypher versus Taxus	patients Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation	
Lipsia-Yukon-DM ongoing [NCT00368953] n=NA follow-up: 9 months	Yukon Choice stent system versus Taxus Libert stent system	Patients With Diabetes Mellitus	
sirolimus eluting stent vs CABG			
PRECOMBAT , 2011 [NCT00422968] n=300/300 follow-up:	PCI with sirolimus-eluting stents versus CABG	patients with unprotected left main coronary artery stenosis	
MIDCAB Versus DES in Proximal LAD Lesions ongoing [NCT00299429] n=NA follow-up:	sirolimus-coated stent versus minimally invasive bypass surgery	patients with isolated proximal left anterior descending coronary arteries	
Munich Study ongoing n=NA	sirolimus versus CABG	-	
sirolimus eluting stent vs Firebird eluting stent			
Gao ongoing [NCT00887211] n=NA follow-up:	ProStent rapamycin-eluting stent system versus Firebird drug-eluting stents	-	Parallel groups single blind

More details and results :

- myocardial revascularization for coronary artery disease in all type of patient at <http://www.trialresultscenter.org/go-Q26>
- myocardial revascularization for coronary artery disease in diabetic patients at <http://www.trialresultscenter.org/go-Q30>
- Drug eluting stent for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q206>
- Drug eluting stent for coronary artery disease in diabetic patients at <http://www.trialresultscenter.org/go-Q207>

- Drug eluting stent for coronary artery disease in acute myocardial infarction at <http://www.trialresultscenter.org/go-Q208>
- Drug eluting stent for coronary artery disease in long or complex lesion at <http://www.trialresultscenter.org/go-Q209>
- Drug eluting stent for coronary artery disease in bypass graft lesion at <http://www.trialresultscenter.org/go-Q210>
- Drug eluting stent for coronary artery disease in in stent restenosis at <http://www.trialresultscenter.org/go-Q211>
- Drug eluting stent for coronary artery disease in unprotected left main artery stenosis at <http://www.trialresultscenter.org/go-Q212>
- Drug eluting stent for coronary artery disease in bifurcation lesion at <http://www.trialresultscenter.org/go-Q214>
- Drug eluting stent for coronary artery disease in unparticular patients at <http://www.trialresultscenter.org/go-Q215>
- Drug eluting stent for coronary artery disease in total occlusion at <http://www.trialresultscenter.org/go-Q216>
- Drug eluting stent for coronary artery disease in small vessels at <http://www.trialresultscenter.org/go-Q217>

References

ISAR-DESIRE (SES vs PTCA), 2005:

Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig A Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71 [[15644543](#)]

BASKET-PROVE (SES), 2010:

Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. N Engl J Med 2010 Nov 16;: [[21080780](#)] [10.1056/NEJMoa1009406](#)

C-SIRIUS, 2004:

Schampaert E, Cohen EA, Schlter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5 [[15028375](#)]

DEBATER (SES vs BMS), 2009:

DECODE, 2005:

unpublished

Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M. Outcomes in diabetic patients with multivessel disease and long lesions: results from the DECODE study Am J Cardiol 2005; 96 (suppl 7A): 31H

DESSERT, 2008:

Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Ugucioni L, Sangiorgio P, Zoccai GB Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 2008;101:1560-6 [[18489933](#)]

DIABETES, 2005:

Sabat M, Jimnez-Quevedo P, Angiolillo DJ, Gmez-Hospital JA, Alfonso F, Hernndez-Antoln R, Goicolea J, Baelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. *Circulation* 2005;112:2175-83 [[16203930](#)]

Jimnez-Quevedo P, Sabat M, Angiolillo DJ, Alfonso F, Hernndez-Antoln R, SanMartn M, Gmez-Hospital JA, Baelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. *Eur Heart J* 2007;28:1946-52 [[17562666](#)]

Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L *Am J Cardiol* 2009 Feb 1;103:345-9 [[19166687](#)]

Daz de la Llera, 2007:

Daz de la Llera LS, Ballesteros S, Nevado J, Fernndez M, Villa M, Snchez A, Retegui G, Garca D, Martnez A Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. *Am Heart J* 2007;154:164.e1-6 [[17584571](#)]

E-SIRIUS, 2003:

Schofer J, Schlter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet* 2003;362:1093-9 [[14550694](#)]

GISSOC II, 2010:

Rubartelli P, Petronio AS, Guiducci V, Sganzerla P, Bolognese L, Galli M, Sheiban I, Chirillo F, Ramondo A, Bellotti S Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. *Eur Heart J* 2010;: [[20566487](#)]
[10.1093/eurheartj/ehq199](#)

Kochiadakis, 2007:

Kochiadakis GE, Marketou ME, Arfanakis DA, Sfridaki K, Skalidis EI, Igoumenidis NE, Hamilos MI, Kolyvaki S, Chlouverakis G, Kantidaki E, Castanas E, Vardas PE, Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. *Atherosclerosis* 2007;194:433-8. [[16997310](#)] [10.1016/j.atherosclerosis.2006.08.029](#)

MISSION, 2008:

van der Hoeven BL, Liem S, Jukema JW, et al. Prospective randomised trial to evaluate the efficacy and safety of drug-eluting stents versus bare-metal stents for the treatment of acute myocardial infarction (the MISSION! intervention study) Annual Scientific Meeting of the American Heart Association. Chicago, IL, USA; Nov 12-15, 2006.

van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. *J Am Coll Cardiol* 2008 Feb 12;51:618-26 [[18261680](#)]

Ortolani et al, 2007:

Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F, Silenzi S, Cooke RM, Reggiani ML, Branzi A Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. *Catheter Cardiovasc Interv* 2007;69:790-8 [[17290437](#)]

Pache et al, 2005:

Pache J, Dibra A, Mehilli J, Dirschinger J, Schmig A, Kastrati A Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. *Eur Heart J* 2005;26:1262-8 [[15737962](#)]

Pasceri, 2003:

unpublished

Pasceri V, Granatelli A, Pristipino C, et al. A randomized trial of arapamycin-eluting stent in acute myocardial infarction: preliminary results TCT 2003. *Am J Cardiol* 2003;92(Suppl 6A):1L.

PRISON II, 2006:

Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. *Circulation* 2006;114:921-8 [[16908768](#)]

RAVEL, 2002:

Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnr F, Falotico R A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002;346:1773-80 [[12050336](#)]

Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. *J Am Coll Cardiol* 2007 Oct 2;50:1299-304 [[17903626](#)]

Ravel (diabetics), 2004:

Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, Wietze L, Sousa JE, Serruys PW, Morice MC Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. *Eur Heart J* 2004;25:107-12 [[14720526](#)]

RRISC, 2006:

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. *J Am Coll Cardiol* 2007 Jul 17;50:261-7 [[17631219](#)]

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. *J Am Coll Cardiol* 2006 Dec 19;48:2423-31 [[17174178](#)]

SCANDSTENT, 2006:

Kelbaek H, Thuesen L, Helqvist S, Klvgaard L, Jrgensen E, Aljabbari S, Saunamki K, Krusell LR, Jensen GV, Btker HE, Lassen JF, Andersen HR, Thayssen P, Galle A, van Weert A The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. *J Am Coll Cardiol* 2006;47:449-55 [[16412876](#)]

Kelbaek H, Klvgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrm T, Btker HE, Jrgensen E, Saunamki K, Aljabbari S, Thayssen P, Galle A, Jensen GV, Thuesen L Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. *J Am Coll Cardiol* 2008 May 27;51:2011-6 [[18498953](#)]

SCANDSTENT (subgroup), 2006:

Kelbaek H, Helqvist S, Thuesen L, Klvgaard L, Jrgensen E, Saunamki K, Krusell LR, Btker HE, Engstrm T, Jensen GV Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. *Am Heart J* 2006;152:882-6 [[17070149](#)] [10.1016/j.ahj.2006.03.028](#)

SCORPIUS, 2007:

Baumgart D. One year results of the SCORPIUS-Trial - a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients Annual Scientific Meeting of the Transcatheter Cardiovascular Therapeutics. Washington, DC; Oct 22-27, 2006. Abstract 288.

Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Vlker W, Pfannebecker T, Stoll HP, Nickenig G One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. *J Am Coll Cardiol* 2007 Oct 23;50:1627-34

[17950142]

SES-SMART, 2004:

Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. *JAMA* 2004;292:2727-34 [15585732]

SES-SMART (diabetics), 2005:

Ortolani P, Ardissino D, Cavallini C, Bramucci E, Indolfi C, Aquilina M, Marzocchi A Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy). *Am J Cardiol* 2005;96:1393-8 [16275185]

SESAMI, 2007:

Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). *J Am Coll Cardiol* 2007;49:1924-30 [17498576]

Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli R Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Results of the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction) Trial. *J Am Coll Cardiol* 2010 Feb 23;55:810-814 [20170821] [10.1016/j.jacc.2009.09.046](https://doi.org/10.1016/j.jacc.2009.09.046)

SIRIUS, 2003:

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003;349:1315-23 [14523139]

Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MB Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). *Am J Cardiol* 2007 Apr 15;99:1044-50 [17437725]

Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. *Circulation* 2004;109:634-40 [14769686]

Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. *J Am Coll Cardiol* 2009 Apr 28;53:1488-97 [19389558] [10.1016/j.jacc.2009.01.050](https://doi.org/10.1016/j.jacc.2009.01.050)

Novack V, Nguyen MC, Rooney M, Chacko R, Novack L, Pencina M, Apruzzese P, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DE Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. *Am J Cardiol* 2010 Sep 15;106:774-9 [20816116] [10.1016/j.amjcard.2010.04.039](https://doi.org/10.1016/j.amjcard.2010.04.039)

SIRIUS (diabetics), 2003:

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003;349:1315-23 [14523139]

Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MB Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). *Am J Cardiol* 2007 Apr 15;99:1044-50 [17437725]

TYPHOON, 2006:

Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C Sirolimus-eluting versus uncoated stents in acute myocardial infarction. *N Engl J Med* 2006;355:1093-104 [16971716]

BASKET-PROVE, 2008:

ongoing trial

Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C, , Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. *Am Heart J* 2008;155:609-14. [[18371466](#)] [10.1016/j.ahj.2007.11.011](#)

CRISTAL, 0:

RIBS-II, 2008:

Alfonso F, Prez-Vizcayno MJ, Hernandez R, Bethencourt A, Mart V, Lopez-Mnguez JR, Angel J, Iiguez A, Mors C, Cequier A, Sabat M, Escaned J, Jimnez-Quevedo P, Bauelos C, Surez A, Macaya C Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. *J Am Coll Cardiol* 2008 Nov 11;52:1621-7 [[18992651](#)]

FOCUS, 0:

ongoing trial NCT00485004

SISR, 2007:

Reynolds MR, Pinto DS, Shi C, Walczak J, Berezin R, Holmes DR, Cohen DJ, Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. *Am Heart J* 2007;154:1221-7. [[18035097](#)] [10.1016/j.ahj.2007.07.033](#)

Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. *JAMA* 2006;295:1264-73 [[16531619](#)]

BASKET (vs paclitaxel), 2005:

Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitts Trial (BASKET). *Lancet* 2005;366:921-9 [[16154019](#)]

Cervinka, 2006:

Cervinka P, Costa MA, Angiolillo DJ, Spacek R, Bystron M, Kvasnk M, Veselka J, Nanda H, Futamatsu H, Futamatsu K "Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study". *Catheter Cardiovasc Interv* 2006;67:846-51 [[16683273](#)]

CORPAL, 2005:

unpublished

de Lezo J, Medina A, Pan M, et al. de Lezo J, Medina A, Pan M, et al. Drug-eluting stent for complexlesions: latest angiographic data from randomized rapamycinversus paclitaxel CORPAL study *J Am Coll Cardiol* 2005; 45: 75A.

DES-DIABETES, 2008:

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ *J Am Coll Cardiol* 2008 Aug 26;52:727-33 [[18718419](#)]

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial. *J Am Coll Cardiol* 2009 Mar 3;53:812-3 [[19245976](#)]

Di Lorenzo et al., 2005:

unpublished

Di Lorenzo E, Varricchio A, Lanzillo T, et al. Paclitaxel and sirolimusstent implantation in patients with acute myocardial infarction (abstr) *Circulation* 2005;112:U538

Han, 2006:

Han YL, Wang XZ, Jing QM, Wang SL, Ma YY, Luan B [Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease] *Zhonghua Xin Xue Guan Bing Za Zhi* 2006;34:123-6 [[16626577](#)]

ISAR-DESIRE (SES vs PES), 2005:

Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig A Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 2005;293:165-71 [[15644543](#)]

ISAR-DESIRE-2, 2010:

Mehilli J, Byrne RA, Tiroch K, Piniack S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schmig A, Kastrati A Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study. *J Am Coll Cardiol* 2010 Mar 5;: [[20226618](#)] [10.1016/j.jacc.2010.02.009](#)

ISAR-DIABETES, 2005:

Dibra A, Kastrati A, Mehilli J, Pache J, Schhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schmig A Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *N Engl J Med* 2005;353:663-70 [[16105990](#)]

ISAR-LEFT-MAIN, 2009:

Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schmig A Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2009 May 12;53:1760-8 [[19422982](#)]

ISAR-SMART 3, 2006:

Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schmig A Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. *Eur Heart J* 2006;27:260-6 [[16401670](#)]

ISAR-TEST-1, 2006:

Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schmig A Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. *Circulation* 2006;113:273-9 [[16391155](#)]

Kim, 2008:

Kim MH, Hong SJ, Cha KS, Park HS, Chae SC, Hur SH, Gwon HC, Bae JH, Lim DS Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. *J Interv Cardiol* 2008 Jun;21:225-31 [[18341520](#)]

LONG DES II, 2006:

Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. *Circulation* 2006;114:2148-53 [[17060388](#)]

Pan, 2007:

Pan M, Surez de Lezo J, Medina A, Romero M, Delgado A, Segura J, Ojeda S, Mazuelos F, Hernandez E, Melian F, Pavlovic D, Esteban F, Herrador J Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. *Am Heart J* 2007 Jan;153:15.e1-7 [[17174630](#)]

Petronio et al, 2007:

Petronio AS, De Carlo M, Branchitta G, Papini B, Ciabatti N, Gistri R, Cortese B, Gherarducci G, Barsotti A Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. *J Am Coll Cardiol* 2007;49:539-46 [[17276176](#)]

PROSIT, 2006:

Lee JH, Kim HS, Lee SW, et al. Prospective randomized trial of sirolimus eluting versus a paclitaxel eluting stent for the treatment of acute ST-elevation myocardial infarction Annual Scientific Meeting of the American College of Cardiology; Atlanta, GA, USA; March 11-14, 2006.

Kornowski R Drug-eluting stents in ST elevation myocardial infarction: In light of the PROSIT trial. Catheter Cardiovasc Interv 2008 Jul 1;72:33-5 [18561153]

Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, Cho Y, Lee N, Rhee KS, Ko JK, Seong IW Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: PROSIT trial. Catheter Cardiovasc Interv 2008 Jul 1;72:25-32 [18412270]

REALITY, 2006:

Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904 [16493102]

REALITY (diabetics), 2006:

unpublished

Windecker S. Cypher is preferred in diabetics 2006 Transcatheter Cardiovascular Therapeutics Annual Meetings

SIRTAX (small vessels subgroup), 2005:

Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lscher TF, Garachemani A, Hess OM, Wandel S, Meier B, Jni P, Windecker S Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007;50:1123-31 [17868802]

SIRTAX (Windecker), 2005:

Windecker S, Remondino A, Eberli FR, Jni P, Rber L, Wenaweser P, Togni M, Billinger M, Tller D, Seiler C, Roffi M, Corti R, Stsch G, Maier W, Lscher T, Hess OM, Egger M, Meier B Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62 [16105989]

SIRTAX diabetics, 2005:

Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lscher TF, Garachemani A, Hess OM, Wandel S, Meier B, Jni P, Windecker S Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007;50:1123-31 [17868802]

Windecker S, Remondino A, Eberli FR, Jni P, Rber L, Wenaweser P, Togni M, Billinger M, Tller D, Seiler C, Roffi M, Corti R, Stsch G, Maier W, Lscher T, Hess OM, Egger M, Meier B Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62 [16105989]

SORT OUT II, 2008:

Galloe AM. prospective multi-center, large-scale, randomized trial of paclitaxel- and sirolimus-eluting stents in real-world lesions Annual Scientific Meeting of the Transcatheter Cardiovascular Therapeutics; Washington, DC; Oct 22-27, 2006

Galle AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamki K, Junker A, Aare J, Abildgaard U, Ravkilde J, Engstrm T, Jensen JS, Andersen HR, Btker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrm SZ, Step Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008;299:409-16 [18230778]

TAXi, 2005:

Goy JJ, Stauffer JC, Siegenthaler M, Benot A, Seydoux C A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005;45:308-11 [15653032]

Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benot A, Goy JJ Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. Catheter Cardiovasc Interv 2007 Aug 1;70:163-6 [17630653]

TAXi (diabetics), 3000:

unpublished

Tomai, 2008:

Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffr G, Prati F, Tamburino C, Ribichini F, Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. *Diabetes Care* 2008;31:15-9. [[17909090](#)] [10.2337/dc07-1377](#)

Wessely, 2008:

Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schmig A Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. *Eur Heart J* 2007 Nov;28:2720-5 [[17921531](#)]

Zhang (SES vs PES), 2006:

Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ni J, Fang YH, Zhang X, Shen WF One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. *Chin Med J (Engl)* 2006;119:165-8 [[16455001](#)]

DES-ISR, 0:

ongoing trial NCT00485030

Lipsia-Yukon-DM, 0:

ongoing trial NCT00368953

PRECOMBAT, 2011:

Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Chung CH, Lee JW, Lim DS, Rha SW, Lee SG, Gwon HC, Kim HS, Chae IH, Jang Y, Jeong MH, Tahk SJ, Seung KB Randomized Trial of Stents versus Bypass Surgery for Left Main Coronary Artery Disease. *N Engl J Med* 2011 Apr 4;: [[21463149](#)] [10.1056/NEJMoa1100452](#)

MIDCAB Versus DES in Proximal LAD Lesions, 0:

ongoing trial NCT00299429

Munich Study, 0:

ongoing trial

Gao, :

ongoing trial NCT00887211

Entry terms: CYPHER,